d8-TT2-32 acetate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 556045

CAS#: d8-TT2-32 acetate

Description: d8-TT2-32 is perphenylanine-deuterated TT2-32 analog. TT2-32, also known as TLN-232 and CAP232, is a somatostatin structural derivative with antitumor activity. TT-232 inhibited tyrosine kinase activity of tumor cell lines and this inhibition correlated well with the inhibition of cell proliferation of a large number of cancer cell lines in vitro and reduces the size of different tumors in animal models in vivo. The antitumor efficacy of TT-232 has been found to be associated with the induction of apoptosis in tumor cells, resulting in highly selective elimination of tumor tissue. TT-232 was found to be devoid of GH release inhibitory activity but to possess strong antitumor effects. It binds with a high affinity to SSTR1 and SSTR4. This compound was also found to inhibit inflammation in a number of experimental models.


Chemical Structure

img
d8-TT2-32 acetate
CAS# d8-TT2-32 acetate

Theoretical Analysis

MedKoo Cat#: 556045
Name: d8-TT2-32 acetate
CAS#: d8-TT2-32 acetate
Chemical Formula: C47H54D8N10O11S2
Exact Mass:
Molecular Weight: 1015.2408
Elemental Analysis: C, 55.60; H, 6.95; N, 13.80; O, 17.33; S, 6.32

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: d8-TT2-32 acetate; deuterated labeled-TT2-32; TT2-32; TT2 32; TT232; TT-232; TT 232; CAP 232; CAP-232; CAP232; TLN-232; TLN 232; TLN232;

IUPAC/Chemical Name: (4R,7S,10R,13S,16R)-10-((1H-indol-3-yl)methyl)-16-((R)-2-amino-3-(phenyl-d5)propanamido-2,3,3-d3)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-7-(4-aminobutyl)-13-(4-hydroxybenzyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecane-4-carboxamide acetate

InChi Key: DPXYLBGOBOVJQG-ZSWOJWCMSA-N

InChi Code: InChI=1S/C45H58N10O9S2.C2H4O2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46;1-2(3)4/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64);1H3,(H,3,4)/t25-,31-,33+,34+,35-,36+,37+,38+;/m1./s1/i2D,3D,4D,9D,10D,19D2,31D;

SMILES Code: O=C([C@@H](NC([C@H](CCCCN)NC([C@@H](CC1=CNC2=C1C=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)NC4=O)=O)=O)=O)CSSC[C@@H]4NC([C@]([2H])(N)C([2H])(C5=C(C([2H])=C(C([2H])=C5[2H])[2H])[2H])[2H])=O)N[C@@H]([C@H](O)C)C(N)=O.CC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1015.2408 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Varona L, Noguera JL, Casellas J, de Hijas MM, Rosas JP, Ibáñez-Escriche N. A cross-specific multiplicative binomial recursive model for the analysis of perinatal mortality in a diallel cross among three varieties of Iberian pig. Sci Rep. 2020 Dec 3;10(1):21190. doi: 10.1038/s41598-020-78346-7. PMID: 33273670; PMCID: PMC7712833.

2: Sun C, Liu M, Zhang W, Wang S, Qian G, Wang M, Zhang G. Overexpression of enolase 2 is associated with worsened prognosis and increased glycikolysis in papillary renal cell carcinoma. J Cell Physiol. 2021 May;236(5):3821-3831. doi: 10.1002/jcp.30130. Epub 2020 Nov 1. PMID: 33135164.

3: Kuriyama I, Miyazaki A, Tsuda Y, Yoshida H, Mizushina Y. Inhibitory effect of novel somatostatin peptide analogues on human cancer cell growth based on the selective inhibition of DNA polymerase β. Bioorg Med Chem. 2013 Jan 15;21(2):403-11. doi: 10.1016/j.bmc.2012.11.024. Epub 2012 Nov 29. PMID: 23266186.

4: Jung Y, Oh SH, Witek RP, Petersen BE. Somatostatin stimulates the migration of hepatic oval cells in the injured rat liver. Liver Int. 2012 Feb;32(2):312-20. doi: 10.1111/j.1478-3231.2011.02642.x. Epub 2011 Sep 14. PMID: 22098068; PMCID: PMC3253984.

5: Szolcsányi J, Pintér E, Helyes Z, Petho G. Inhibition of the function of TRPV1-expressing nociceptive sensory neurons by somatostatin 4 receptor agonism: mechanism and therapeutical implications. Curr Top Med Chem. 2011;11(17):2253-63. doi: 10.2174/156802611796904852. PMID: 21671870.

6: Kuriyama I, Miyazaki A, Tsuda Y, Yokoi T, Okada Y, Takeuchi T, Sugawara F, Yoshida H, Mizushina Y. Inhibitory effect of somatostatin Peptide analogues on DNA polymerase activity and human cancer cell proliferation. Anticancer Res. 2010 Dec;30(12):4841-9. PMID: 21187461.

7: Tejeda M, Gaal D, Hullán L, Csuka O, Schwab R, Szokoloczi O, Kéri GY. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. Anticancer Res. 2008 Sep-Oct;28(5A):2769-74. PMID: 19035308.

8: Miyazaki A, Tsuda Y, Fukushima S, Yokoi T, Vántus T, Bökönyi G, Szabó E, Horváth A, Kéri G, Okada Y. Synthesis of somatostatin analogues containing C-terminal adamantane and their antiproliferative properties. J Med Chem. 2008 Aug 28;51(16):5121-4. doi: 10.1021/jm701599w. Epub 2008 Aug 5. PMID: 18680358.

9: Tejeda M, Gaál D, Hullán L, Schwab R, Szokoloczi O, Kéri G. Antitumor activity of the somatostatin structural derivative (TT-232), against mouse and human melanoma tumor models. Anticancer Res. 2007 Nov-Dec;27(6B):4015-9. PMID: 18225564.

10: Elekes K, Helyes Z, Kereskai L, Sándor K, Pintér E, Pozsgai G, Tékus V, Bánvölgyi A, Németh J, Szuts T, Kéri G, Szolcsányi J. Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse. Eur J Pharmacol. 2008 Jan 14;578(2-3):313-22. doi: 10.1016/j.ejphar.2007.09.033. Epub 2007 Oct 5. PMID: 17961545.

11: Steták A, Veress R, Ovádi J, Csermely P, Kéri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007 Feb 15;67(4):1602-8. doi: 10.1158/0008-5472.CAN-06-2870. PMID: 17308100.

12: Tejeda M, Gaál D, Hullán L, Hegymegi-Barakonyi B, Kéri G. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Anticancer Res. 2006 Sep-Oct;26(5A):3477-83. PMID: 17094470.

13: Tejeda M, Gaál D, Hullán L, Csuka O, Schwab R, Szokoloczi O, Kéri G. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. Anticancer Res. 2006 Jul-Aug;26(4B):3011-5. PMID: 16886628.

14: Szokolóczi O, Schwab R, Peták I, Orfi L, Pap A, Eberle AN, Szüts T, Kéril G. TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. J Recept Signal Transduct Res. 2005;25(4-6):217-35. doi: 10.1080/10799890500464621. PMID: 16393913.

15: Tejeda M, Gaál D, Csuka O, Kéri G. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Res. 2005 Jan-Feb;25(1A):325-30. PMID: 15816555.

16: Szolcsányi J, Bölcskei K, Szabó A, Pintér E, Petho G, Elekes K, Börzsei R, Almási R, Szuts T, Kéri G, Helyes Z. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia. Eur J Pharmacol. 2004 Sep 13;498(1-3):103-9. doi: 10.1016/j.ejphar.2004.07.085. PMID: 15363982.

17: Helyes Z, Szabó A, Németh J, Jakab B, Pintér E, Bánvölgyi A, Kereskai L, Kéri G, Szolcsányi J. Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. Arthritis Rheum. 2004 May;50(5):1677-85. doi: 10.1002/art.20184. PMID: 15146439.

18: Simon A, Czajlik A, Perczel A, Kéri G, Nyikos L, Emri Z, Kardos J. Binding crevice for TT-232 in a homology model of type 1 somatostatin receptor. Biochem Biophys Res Commun. 2004 Apr 16;316(4):1059-64. doi: 10.1016/j.bbrc.2004.02.161. PMID: 15044092.

19: Kéri G, Racz G, Magyar K, Orfi L, Horváth A, Schwab R, Hegymegi BB, Szende B. Pro-apoptotic and anti-apoptotic molecules affecting pathways of signal transduction. Ann N Y Acad Sci. 2003 Dec;1010:109-12. doi: 10.1196/annals.1299.018. PMID: 15033704.

20: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. PMID: 14988742.